New Indication: Repotrectinib for NTRK-Fusion Positive Solid Tumors

  • Study

    Advanced NTRK-fusion+ solid tumors (TRIDENT-1)
    TKI-naive (n=40) and TKI-pretreated (n=48)

  • Efficacy

    NSCLC was most common type. Salivary gland cancer, thyroid cancer, sarcoma, and others
    ORR: 58% and 50%
    12-mo PFS: 86% and 39%

  • Safety

    Grade >3 AEs: 51%


    • Annals Oncol 2023;34:S787

    Solomon BJ Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

    http://doi.org/10.1016/j.annonc.2023.09.2405

    Reviewed by Ulas D. Bayraktar, MD on Jun 21, 2024

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag